UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

Partnering with UCSF HDFCCC UCSF faculty have a long history of working with industry partners translating discoveries into products that ultimately improve patient care. We are experienced in establishing and executing on a wide range of successful partnerships. If you are interested in learning more about working with the HDFCCC and its faculty, please contact: Cammie Edwards, PhD Director of Strategic Alliances, HDFCCC • On average, UCSF has 200-300 new invention disclosures per year • An estimated 90 life science start-up companies have been spawned from the University’s labs, including Genentech, Chiron, and Intellikine • Included among UCSF patents are top revenue producers, such as - Hepatitis B vaccine - Bovine growth hormone - Barrier repair lipids - Yeast expression vector - Magnetic resonance imaging UCSF IN THE NEWS (Click on title to read story) AACR Elects UCSF’s Alan Ashworth and Jennifer Grandis to Board of Directors, Nominating Committee http://cancer.ucsf.edu/news/2016/04/11/american-association-for-cancer-research-elects-ucsf-faculty-to-board-of-directors-nominating-committee.7420 VP Biden Discusses Cancer Moonshot with UCSF Experts http://cancer.ucsf.edu/news/2016/03/02/vp-biden-discusses-cancer-moonshot-with-ucsf-experts.7355 BRCA Clinics Expand Further Beyond Breast Cancer: New thinking on pancreatic, prostate cancer treatment; centers consolidate patient care under one roof http://cancer.ucsf.edu/news/2016/02/22/brca-clinics-expand-further-beyond-breast-cancer.7315 UCSF Establishes Quantitative Biosciences Institute: New Research Unit will Identify Opportunities for Disease Treatments Using Computation, Mathematics and Statistics http://cancer.ucsf.edu/news/2016/03/17/ucsf-establishes-quantitative-biosciences-institute.7376 UCSF Research Suggests New Model for Cancer Metastasis: Imaging Catches Cancer Cells in the Act As They Recruit Immune Cells to Spread Disease http://cancer.ucsf.edu/news/2016/03/17/ucsf-research-suggests-new-model-for-cancer-metastasis.7374 Melanoma’s Genetic Trajectories Are Charted in New Study: Study Confirms ‘Intermediate’ Disease Stage Between Benign Moles and Malignancy http://cancer.ucsf.edu/news/2015/11/12/melanomas-genetic-trajectories-are-charted-in-new-study.6907
Presentations Presentations View full abstracts on line at: http://www.abstractsonline.com/plan/start.aspx?mkey=%7b1D10D749-4B6A-4AB3-BCD4-F80FB1922267%7d *UCSF authors in bold E-cigarettes: Expanding the Nicotine Epidemic Authors*: Lauren Dutra Pres #: Section: Presentation Date/Time: Sunday, April 17: 3:00-4:30PM Location: Room 283 Presentation Type: Science Policy Session Lauren Dutra Expertise: Lauren Dutra’s research interests include disparities in smoking and smokingrelated disease, the targeted marketing of vulnerable populations by tobacco companies, and new tobacco products, such as e-cigarettes. She has a Doctor of Science from the Harvard School of Public Health and is a Social Epidemiologist by training. Her dissertation focused on experiences of injustice and smoking behavior in South Africa and the US. Prior to obtaining her doctorate, she received a Masters in Mental Health and Behavioral Medicine from Boston University and worked as a psychotherapist/health behavior counselor. Lauren has first-author publications in Social Science & Medicine, JAMA Pediatrics, and Tobacco Control, as well as publications in Preventive Medicine, Diabetes Care, and the Journal of Cognitive Psychology. http://profiles.ucsf.edu/lauren.dutra __________________________________________________________________________ MEK and PI3K signaling cooperate through mTORC1/2 to promote PIK3CA mutant melanoma cell proliferation Authors*: Jillian M. Silva, Marian M. Deuker, Bruce C. Baguley, Martin McMahon Pres #: 29 Section: 1 Presentation Date/Time: Sunday, April 17: 1:00-5:00PM Location: Presentation Type: Poster Session Silva Lab Expertise: The overarching goal of the Silva lab research is to understand the underlying molecular and biochemical mechanisms of cooperation between key signaling networks, such as MAPK and PI3K, that are essential for carcinoma maintenance and to identify potential molecular targets that could contribute to the development of pathway-targeted therapy for cancer patients. We use cutting-edge screening technologies, such as a lentiCRISPR-Cas9 knockout library and ribosome profiling, along with genetic/ pharmacological inhibitory strategies and xenograft tumor models to dissect out the these key kinase mechanisms and the consequences of their inhibition. Melonoma is our primary model system, but we apply our discoveries to other types of cancer that share similar molecular and biochemical landscapes. http://profiles.ucsf.edu/jillian.silva *UCSF authors in bold 7
Page 1 and 2: UCSF HELEN DILLER FAMILY COMPREHENS
Page 3 and 4: HDFCCC Overview A Designated NCI Co
Page 5: HDFCCC Overview Core Capabilities S
Page 9 and 10: Presentations Whole exome and targe
Page 11 and 12: Presentations SRC mediates intrinsi
Page 13 and 14: Presentations Deregulated Myc is an
Page 15 and 16: Presentations BRM loss promotes tum
Page 17 and 18: Presentations HER3 is a functional
Page 19 and 20: Presentations MicroRNA-466 regulate
Page 21 and 22: Presentations Systematic search for
Page 23 and 24: Presentations Toxicity, bioavailabi
Page 25 and 26: Presentations The genetic evolution
Page 27 and 28: Presentations A stem cell program i
Page 29 and 30: Presentations Inhibition of fatty-a
Page 31 and 32: Presentations Genetic prediction of
Page 33 and 34: Presentations Overcoming resistance
Page 35 and 36: Presentations Direct analysis of tu
Page 37: Presentations Caffeic acid phenethy

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Create successful ePaper yourself

Delete template?

Save as template?